Literature DB >> 24393953

[Long-term survival of a patient with locally advanced unresectable pancreatic cancer treated with gemcitabine after chemoradiation therapy].

Teruhiro Chohno1, Taro Aoki, Satoshi Hyuga, Risa Watanabe, Takashi Matsumoto, Hiroyoshi Takemoto, Kou Takachi, Kiyonori Nishioka, Yoshio Uemura, Kenji Kobayashi.   

Abstract

We report a case of long-term survival of a patient with locally advanced unresectable pancreatic cancer treated with gemcitabine after chemoradiation therapy( CRTx). A 61-year-old woman was diagnosed as having locally advanced unresectable pancreatic cancer, 3.0 cm in diameter, which had invaded the superior mesenteric artery by computed tomography (CT). She was treated with CRTx( gemcitabine[ GEM] at 250 mg/m2/week for 6 weeks+liniac irradiation of 50.2 Gy) followed by systemic chemotherapy (gemcitabine (GEM) at 1,000 mg/m2). Reassessment after CRTx yielded a diagnosis of stable disease (according to the Response Evaluation Criteria in Solid Tumors [RECIST] 1.1). To date, the patient has undergone 57 courses of chemotherapy in the outpatient clinic; however, she did require biliary stent placement because of occlusive jaundice.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24393953

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  2 in total

1.  Rare long-term survivors of pancreatic adenocarcinoma without curative resection.

Authors:  Stephen Y Oh; Alicia Edwards; Margaret T Mandelson; Bruce Lin; Russell Dorer; W Scott Helton; Richard A Kozarek; Vincent J Picozzi
Journal:  World J Gastroenterol       Date:  2015-12-28       Impact factor: 5.742

2.  Unresectable Pancreatic Adenocarcinoma: Eight Years Later.

Authors:  Kate Smiley; Reetu Malhotra; William Peche; John T Langell
Journal:  World J Oncol       Date:  2016-04-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.